ClinicalTrials.gg
RecruitingNCT07349706Updated Nov 4, 2026

IMST for Dementia Risk Reduction

An interventional study of Inspiratory Muscle Strength Training High-Resistance and Inspiratory Muscle Strength Training Low-Resistance in Systolic Blood Pressure, Blood Pressure and Depression - Major Depressive Disorder, sponsored by Florida State University. Recruiting at 1 site in United States. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Florida State University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 4, 2026Study documents postedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Study summary

Using a 2-arm, RCT approach, the primary goal of the study is to evaluate the feasibility and preliminary efficacy of Inspiratory Muscle Strength Training (IMST) as a non-pharmacologic intervention to reduce cardiovascular and cognitive risks in older adults. Next, investigators will examine secondary effects of IMST on mood, sleep quality, systemic inflammation, and physical/motor function. Finally, investigators will assess participant adherence and acceptability ratings of using an 8-week home-based IMST protocol in a diverse older adult sample.

Read the detailed description

This is a 2-arm randomized pilot trial (N=30), including adults aged 60-80 years of age with cardiovascular risks for dementia. Participants will complete assessments prior to beginning the study, each week during the intervention, and at the conclusion of the 8-week intervention. Participants in the experimental group will complete daily high-resistance IMST training (e.g., 75% maximal inspiratory pressure), and participants in the sham condition will complete IMST training at 15% maximal inspiratory pressure. Investigators hypothesize the following: Hypothesis 1: Participants in the high-resistance IMST group will show greater reductions in systolic blood pressure and other vascular health indicators compared to those in the sham IMST group after 8 weeks.

Hypothesis 2: Participants in the high-resistance IMST group will demonstrate greater improvements in executive cognitive function than those in the sham group.

Hypothesis 3: IMST will lead to secondary improvements in mood (reduced depression and anxiety symptoms), better sleep quality (as measured by self-report and actigraphy), and improved physical function (e.g., grip strength, gait speed).

Hypothesis 4: The IMST protocol will be feasible and acceptable, with at least 80% adherence to prescribed training sessions over the 8-week period.

02

Conditions studied

  • Systolic Blood Pressure
  • Blood Pressure
  • Depression - Major Depressive Disorder
  • Anxiety
  • Sleep Quality
  • Physical Function
  • Cognitive Function

Browse trials for

03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 30 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 60-80
  • Converted telephone total score≥18
  • Presence of at least one dementia risk factor (e.g., MCI or subjective cognitive decline, hypertension [SBP >130 mmHg or on medication], sedentary lifestyle [\<150 min/week], family history of dementia or self-reported APOE ε4 carrier, or mild sleep-disordered breathing; CAIDE total score [>5]
  • Capable of independently completing or requiring minimal assistance with inspiratory muscle strength training (IMST)
  • Willing to adhere to the IMST protocol (approximately 5-10 minutes per day for 8 weeks)
  • Optional inclusion of inspiratory muscle weakness (MIP \<80 cmH₂O for men, \<70 cmH₂O for women) will also be assessed.

Exclusion criteria

Exclusion Criteria:

  • tMoCA \<18, or diagnosis of neurodegenerative illness at the discretion of principal investigator (except MCI)
  • Current evidence of any major psychiatric disorder including psychosis (at the discretion of principal investigator), bipolar disorder, severe major depression (PHQ-9 > 20)
  • Unstable cardiovascular or pulmonary disease
  • Recent respiratory therapy or major medication changes
  • Self-reported severe untreated or unstable obstructive sleep apnea (OSA)
  • Recent start (within the past month) of CPAP or BiPAP, or recent use of inspiratory muscle training
  • Lung and eardrum injuries
  • Non-English speaking
  • Participants with a pacemaker or other medical implants containing magnets or electronics will be noted and excluded from body composition analyses.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-Resistance

    Participants assigned to the high resistance arm will complete inspiratory muscle strength training (IMST) using a handheld respiratory training device set to 75% of their maximal inspiratory pressure (MIP). Participants will follow the IMST training regimen for the duration of the intervention period, 8-weeks, consisting of 30 breaths per day, completed in a minimum of 5 minutes.

    Device: Inspiratory Muscle Strength Training High-Resistance

  • Sham comparator
    Control Group - Low-Resistance

    Participants assigned to the low-resistance arm will complete inspiratory muscle strength training (IMST) using a handheld respiratory training device set to 15% of their maximal inspiratory pressure (MIP). Participants will follow the IMST training regimen for the duration of the intervention period, 8-weeks, completing 30 inspiratory breaths per day, with each session lasting a minimum of 5 minutes.

    Device: Inspiratory Muscle Strength Training Low-Resistance

Interventions

  • DeviceInspiratory Muscle Strength Training High-Resistance

    Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 75% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.

  • DeviceInspiratory Muscle Strength Training Low-Resistance

    Investigators will use POWERbreathe® Electronic IMST devices and manually set them to 15% of an individual's IPpeak, depending on their randomization, to the high-resistance IMST group or very low-resistance IMST (sham) group. All participants will complete 30 training breaths per day at home for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in systolic BP

    Participants will demonstrate a change in systolic blood pressure (mmHg), assessed as the average of two seated measurements obtained following two consecutive 5-minute rest periods, from baseline to post-intervention.

    Time frame: Baseline, 8-weeks

  2. Change in executive cognitive functioning

    Participants will demonstrate a change in executive cognitive functioning, assessed using the Fluid Composite Score from the NIH Toolbox Cognition Battery. The Fluid Composite Score is derived from tasks assessing executive function, attention, working memory, episodic memory, and processing speed. Change in executive cognitive functioning will be evaluated as the difference in Fluid Composite Scores from baseline to post-intervention.

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Change from Baseline in Mood Symptoms (Depression) at 8 Weeks

    Participants will demonstrate a change in depression symptoms, assessed using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms. Total scores of 5, 10, 15, and 20 represent cut off points for mild, moderate, moderately severe and severe depression. Change in symptoms will be evaluated as the difference in scores from baseline to 8 weeks, with higher scores indicating greater symptom severity.

    Time frame: Baseline, 8 weeks

  2. Change from Baseline in Mood Symptoms (Anxiety) at 8 Weeks

    Participants will demonstrate a change in anxiety symptoms, assessed using the Geriatric Anxiety Scale-10 (GAS) for anxiety symptoms. Total scores range from 0 to 30, with higher scores indicating greater symptom severity. Change in symptoms will be evaluated as the difference in scores from baseline to 8 weeks, with higher scores indicating greater severity.

    Time frame: Baseline, 8 weeks

  3. Change from Baseline in Sleep Quality at 8 Weeks

    Participants will demonstrate a change in sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI) and objective sleep measures collected via actigraphy (Fitbit) devices provided to participants. Change in sleep quality will be evaluated as the difference in PSQI global scores, with higher scores indicating poorer sleep quality, and sleep metrics compiled from actigraphy data from baseline to 8 weeks.

    Time frame: Baseline, 8 weeks

  4. Change from Baseline in Inflammatory Markers (CRP, IL-6, TNF-α) at 8 Weeks

    Participants will demonstrate a change in inflammatory markers, assessed from fasting blood samples. Serum concentrations of CRP, IL-6, and TNF-α will be measured using standardized laboratory analyses. Change in inflammatory markers will be evaluated from baseline to 8 weeks.

    Time frame: Baseline, 8 weeks

  5. Change from Baseline in Physical Functioning (Grip-Strength) at 8 Weeks

    Participants will demonstrate a change in physical functioning, assessed using grip strength. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Higher grip strength performance indicate improved physical functioning.

    Time frame: Baseline, 8 weeks

  6. Change from Baseline in Physical Functioning (Gait Speed) at 8 Weeks

    Participants will demonstrate a change in physical functioning, assessed using gait speed. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Faster gait speed performance indicate improved physical functioning.

    Time frame: Baseline, 8 weeks

  7. Change from Baseline in Physical Functioning (Sit-to-Stand) at 8 Weeks

    Participants will demonstrate a change in physical functioning, assessed using the sit-to-stand test. Change in physical functioning will be evaluated from baseline to 8 weeks based on performance across these standardized physical function measures. Improved sit-to-stand performance indicate improved physical functioning.

    Time frame: Baseline, 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect the privacy and confidentiality of the participants.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 15 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 20, 2026
StartActual
Nov 17, 2025
Primary completionEst.
Feb 2027was Oct 2026
CompletionEst.
Feb 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Feb 2027
Nov 4, 2026
Study completion
Dec 2026→Feb 2027
Nov 4, 2026
Documents
Oct 5, 2026
Show all 2 updates
  1. Nov 4, 2026
    Primary completion Oct 2026→Feb 2027
    Study completion Dec 2026→Feb 2027
    + 1 other change: verification date
  2. Oct 5, 2026
    Documents Study protocol ↗ posted
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07349706
Responsible party
Julia Sheffler (Assistant Professor, Florida State University) — Principal investigator
First posted
Jan 20, 2026
Start date
Nov 17, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion